HumanFirst unveils new enterprise platform to accelerate AI in clinical research

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags AI Clinical research Artificial intelligence Clinical trial

HumanFirst, a cloud-based software company accelerating patient-centered drug development through AI, has announced the launch of its precision measures platform.

According to the company, the platform is a first-of-its-kind in the industry and will enable pharma and biotechs to incorporate patient-centric measures and validated technologies into clinical research.

In beta tests of HumanFirst’s Atlas platform over the past year, an Alzheimer’s study launched 3 months faster using the platform to evaluate evidence and select the right digital health technology for the research.

In addition, a pilot trial to develop a new digital biomarker for pain was launched 7 months faster by using Atlas to select a single, wrist-worn sensor as the right technology

HumanFirst’s new solution aligns AI-powered biomarkers and clinical outcome assessments (COAs) across one platform to drive scientific progress, R&D efficiencies, and patient-centered research

With life science organizations under pressure to increase R&D efficiency and participant diversity, AI-powered biomarkers and COAs are poised to revolutionize drug development.

Recent regulatory support for AI-powered measures and sensor-derived primary endpoints from the US Food and Drug Administration (FDA) has rapidly accelerated biopharma's investment in AI strategies, with the potential for huge patient impact.

Therefore, HumanFirst is aiming to address this need by evolving its Atlas network into a cloud-based enterprise platform for precision measures spanning DHTs, questionnaires, imaging and blood and fluid-based markers.

Life science organizations seeking to accelerate drug development by investing in AI can now partner with HumanFirst to access the Atlas platform.

HumanFirst is aiming to help life science organizations best leverage the trove of data and research that exists to bring treatments to market faster.

Andy Coravos, CEO and co-founder of HumanFirst, said: “We at HumanFirst have been, and continue to be, the single largest database of AI-powered biomarkers and COAs, with our data that tracks research from more than 850 sponsors. As navigating AI has become an imperative for all of pharma, I’m excited that with today’s announcement, HumanFirst now offers a solution for the entire enterprise to reduce costs, accelerate development, and bring better treatments to market faster.”

Related news

Show more